Overview of Metagon

What is Metagon? (Promethazine Hydrochloride)

Property	Description
Active ingredient	Promethazine Hydrochloride
Forms	Tablet, Syrup, Suppository, Solution (Injection)
Pharmacological class	First-Generation Antihistamine, Phenothiazine Derivative
General purpose	Provides calming relief, treats allergic symptoms, and acts against nausea and vomiting.
Origin	Synthetic compound

What Type of Medicine is Metagon?

Metagon is a pharmaceutical product whose active substance is Promethazine Hydrochloride (INN: Promethazine), formally classified as a First-Generation Antihistamine and a phenothiazine derivative. This compound is a synthetic, single-ingredient drug that primarily operates by blocking the action of histamine at the H1-receptor sites, the body’s primary mechanism for initiating allergic reactions. This structural classification is fundamental to its differentiation from newer, non-sedating antihistamines. Its capacity to readily cross the blood-brain barrier is a hallmark of the first-generation class, which contributes to its additional sedative properties.

Composition and Available Forms of Promethazine HCl

The composition of this medicine centers on the active ingredient, Promethazine Hydrochloride, prepared with various pharmaceutical vehicles. Promethazine is available in a variety of dosage forms, including the oral tablet, the oral syrup (a liquid vehicle), the rectal suppository, and an aqueous solution intended for parenteral administration (injection). This broad range of forms, spanning oral, rectal, and parenteral routes, allows for administration even when oral intake is not tolerated, such as during episodes of severe nausea. The syrup formulation, often flavored, is specifically intended for individuals who have difficulty swallowing solids.

What is the General Benefit Profile of Metagon?

Metagon’s general therapeutic benefit stems from its dual action: managing histamine response and influencing the central nervous system. By suppressing histamine, the medicine provides broad relief from symptoms associated with allergic conditions. Crucially, its CNS activity, which includes strong sedative properties and the interruption of nerve signals to the brain's vomiting center, means the medicine's utility extends to purposes beyond standard allergy treatment. Due to these antiemetic and sedative actions, it is utilized for situations requiring relief from nausea and for providing calming relief.

Regulatory References

parenteral administration

What side effects are possible with Metagon?

Possible Side Effects and Safety Information

The officially documented safety profile of Promethazine Hydrochloride, the active ingredient in Metagon, is characterized by its high propensity for effects on the Central Nervous System and its potential for severe, though less frequent, adverse reactions affecting multiple physiological systems. The medicine's safety data is formally categorized in regulatory documents, such as the FDA Prescribing Information and European Summary of Product Characteristics (SmPC).

Commonly Documented Adverse Reactions

Sedation or drowsiness is the most prominent adverse reaction documented in official labeling. Regulatory texts note that this effect is generally most pronounced at the start of treatment or following an adjustment to a higher dosage. Other commonly listed effects include anticholinergic manifestations such as dry mouth, dizziness, constipation, and blurred vision. Reactions are typically grouped by System-Organ Class (SOC), including Nervous System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders (e.g., photosensitivity).

Serious Adverse Reactions and Regulatory Constraints

A number of serious adverse reactions are explicitly documented in regulatory text, including profound respiratory depression, which can be fatal, and a rare, potentially life-threatening reaction known as Neuroleptic Malignant Syndrome (NMS). Serious effects on the blood, such as agranulocytosis, and the heart, including Torsades de Pointes (an abnormal heart rhythm), are also documented.

The regulatory safety profile includes absolute contraindications regarding use in specific patient populations. Promethazine is strictly contraindicated in pediatric patients younger than two years of age due to the heightened risk of fatal respiratory depression in this group. Older adults may experience increased susceptibility to central nervous system effects such as confusion and dizziness, as noted in government-approved prescribing information.

Overdose and Emergency Response

Overdosage with Metagon (Promethazine Hydrochloride) is officially documented to manifest through a combination of severe central nervous system (CNS) effects. These can include initial confusion and agitation, hallucinations, or paradoxically, profound drowsiness progressing to a coma and unresponsiveness. Other documented clinical signs include convulsions or seizures, involuntary motor movements, rapid heartbeat (tachycardia), dry mouth, and an inability to urinate (urinary retention).

The official profile cites the risk of life-threatening systemic events, including severe respiratory depression, specific cardiac rhythm irregularities (arrhythmias), and the onset of Neuroleptic Malignant Syndrome (NMS). A critical regulatory note highlights that sudden death has been documented, especially when excessively large dosages are administered to children.

Immediate emergency medical help is mandated upon the observation of any severe signs, such as a person collapsing, having a seizure, experiencing difficulty breathing, or becoming unresponsive. Treatment for overdose is classified as symptomatic and supportive, aiming to maintain the patient's respiratory and circulatory status. Regulatory documents confirm that no specific antidote is known for promethazine overdose, and specific guidance is provided against using Epinephrine to manage associated low blood pressure. Due to documented higher risk, specific cautions apply to pediatric and elderly patients.

Therapeutic Uses of Metagon

The therapeutic use of Metagon is associated with symptomatic relief across key domains, commonly used in settings where short-term symptomatic assistance is needed to address acute or disruptive symptom patterns. These applications include the management of allergic conditions, control of nausea and vomiting, and supportive sedation.

Metagon is commonly used across conditions characterized by periods of heightened symptoms stemming from histamine release, such as seasonal allergic rhinitis, allergic conjunctivitis, and uncomplicated allergic skin manifestations like hives (urticaria). The medication is applied in addressing symptom clusters related to nausea, dizziness, and active vomiting (e.g., motion sickness or postoperative distress), and is relevant in situations requiring temporary assistance in symptom stabilization and calming support before procedures. It helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations, and assists with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Management of Nausea and Allergic Itching Metagon is applied in addressing symptoms related to heightened physiological activity and systemic distress, supporting general well-being during symptomatic phases.

Regulatory References

NIH DailyMed Label for Promethazine Hydrochloride

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Metagon — official regulatory information

The official eligibility for Metagon (Promethazine Hydrochloride) is defined by strict regulatory categories, focusing on age, co-existing conditions, and physiological status.

Scope	Regulatory Statement (Strictly Label-Based)
Populations for whom use is allowed	Adults and children two (2) years of age and older (US FDA). Some international labels restrict oral use to children six (6) years of age and older.
Populations for whom use is not recommended	Use is generally not recommended in breastfeeding or during the late third trimester of pregnancy. Not recommended for patients who have used Monoamine Oxidase Inhibitors (MAOIs) within the previous 14 days.
Populations for whom use is contraindicated	Children less than two (2) years of age in all formulations due to the potential for fatal respiratory depression. Patients in a comatose state, with severe CNS depression, or with a known hypersensitivity to promethazine or other phenothiazines. Contraindicated for lower respiratory tract symptoms, including asthma.

Eligibility Classifications

Official eligibility statements:

The medicine is contraindicated for all individuals under two years of age. Some international labels extend the oral formulation contraindication to children under six years.
Use requires specific caution in patients with conditions aggravated by anticholinergic effects, such as narrow-angle glaucoma or prostatic hypertrophy.
Older adults must be administered the drug with caution due to increased susceptibility to sedating effects.
Caution is required for patients with hepatic (liver) or renal (kidney) impairment, seizure disorders, and cardiovascular disease.

Connection to the overall eligibility profile: Official regulatory documents define non-eligibility through absolute contraindications (age, CNS status) and establish conditional use statements that mandate caution or restriction for populations with specific organ impairment, chronic comorbidities, or during specific physiological states like late-term pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metagon’s interaction profile is characterized by documented additive pharmacodynamic effects and explicit regulatory prohibitions, derived exclusively from authoritative government labeling.

Contraindicated Combinations and Major Restrictions

The medicine is strictly contraindicated for use in pediatric patients younger than two years of age due to the potential for fatal respiratory depression. It is also contraindicated with Monoamine Oxidase Inhibitors (MAOIs), and official labeling specifies that use must be avoided for up to 14 days following MAOI therapy due to the risk of intensifying central nervous system (CNS) and anticholinergic effects. Epinephrine is prohibited for use in treating hypotension associated with Promethazine overdose, as the drug’s alpha-blocking activity may reverse Epinephrine's vasopressor effect.

Pharmacodynamic and Metabolic Interactions

Co-administration with other CNS depressants (including alcohol, narcotics, sedatives, and tricyclic antidepressants) may increase, prolong, or intensify sedative action; this additive effect is a primary concern documented in regulatory labeling. The effects of other anticholinergic agents and antihypertensive agents may also be potentiated. A specific pharmacokinetic interaction is documented with Beta Blockers (e.g., Propranolol), which may result in increased plasma concentrations of both agents due to the inhibition of metabolism. The drug may also lower the convulsion threshold, a consideration for co-administration with anticonvulsant medications.

Procedural Constraints

Promethazine must be discontinued at least 72 hours before allergen skin testing to prevent inhibition of the histamine response, which could interfere with the diagnostic result.

Mechanism of Action

Metagon (Promethazine Hydrochloride) exerts its actions through non-selective competitive antagonism across three key central and peripheral receptor systems, thereby inhibiting neural and chemical signaling pathways. The molecule’s high lipophilicity is a critical mechanistic factor, enabling rapid penetration into the central nervous system ( CNS) to engage these targets quickly.

Modulating Arousal via Central Histamine and Acetylcholine Blockade

Promethazine acts as an antagonist at Histamine H1 and Muscarinic Acetylcholine receptors in the brain. By competitively blocking these receptor sites, the drug suppresses signaling sequences associated with wakefulness and alertness. This action reduces the output of neural activity in targeted brain regions, producing a state of CNS depression.

Interfering with the Central Emetic Pathway

This mechanism involves the drug’s antagonism of Dopamine D2 receptors within the Chemoreceptor Trigger Zone ( CTZ) and concurrent anticholinergic action on the vestibular system. This multi-target blockade modifies early molecular steps that coordinate the body's emetic reflex. This systemic interference interrupts the transmission of afferent signals to the vomiting center, resulting in the modulation of emetic reflex activity.

Dosage and Administration Information

The administration of Metagon is based on established protocols. The approved routes of administration include oral (tablet, syrup), rectal (suppository), and parenteral. For injection, deep intramuscular (IM) administration is the preferred method, while intravenous (IV) use is permitted only under strict procedural controls; subcutaneous and intra-arterial routes are explicitly prohibited.

Dosing is variable and depends on the specific use context. Schedules range from a single dose taken at bedtime for certain allergic conditions to doses of 12.5 mg to 25 mg repeated every four to six hours for active nausea and vomiting. For oral intake, the medicine should be administered with food, water, or milk to help mitigate potential gastrointestinal discomfort.

Special administration requirements apply to the injection solution. Intravenous administration requires the drug solution to be diluted to a specific concentration and infused slowly at a rate not exceeding 25 mg/ minute through a large, patent vein. Furthermore, when the medicine is used adjunctively with narcotics or barbiturates for sedation, the dose of those co-administered agents must be reduced.

Administration is contraindicated for children under two years of age, and for older pediatric patients, the dose should be based on factors like weight and should always be the lowest effective amount. These parameters define the procedural how-to-use framework for Promethazine, ensuring that administration follows the standardized method, timing, and dose ranges.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metagon (Promethazine Hydrochloride)

Evidence for Use in Allergic Conditions

Research exploring the use of Metagon for allergy symptoms mainly consists of older short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that synthesize those trials. This evidence was generally used in research contexts involving fluctuating or unstable symptoms caused by histamine release, such as seasonal allergies and hives (urticaria). Studies monitored outcomes related to symptom intensity, including physical discomfort like sneezing, itching, and nasal discharge.

In these trials, researchers examined the medicine in both adults and children aged 2 years and older. Research describes changes measured during the study period, with studies monitoring how symptoms evolved in the observed populations during periods of increased symptom activity. The findings describe patterns observed in the studies concerning the visibility and patient-reported outcomes describing perceived discomfort from allergic skin and nasal manifestations.

It is important to understand that much of the available evidence is historical. As a result, long-term outcomes regarding the repeated use of Metagon for chronic or recurrent allergic conditions are not well characterized by large, contemporary studies. Evidence is also limited for direct comparisons against agents in the same therapeutic class using modern RCT designs, making subgroup findings uncertain.

Evidence for Use in Nausea and Vomiting

Metagon was studied for its use in managing nausea and vomiting across various acute settings, including after surgical procedures and during episodes of motion sickness. The evidence base includes a range of RCTs, Meta-analyses, and Observational Studies. These studies monitored outcomes linked to functional imbalance, specifically looking at the frequency of vomiting episodes and the severity of nausea using standardized measurement tools.

Research examined short-term symptom changes, focusing on episodes where symptoms become more noticeable. In these research scenarios, studies reported how symptoms evolved in the observed populations, and the data show patterns related to the evaluation of the need for rescue medication in certain acute situations. Findings describe group patterns related to these outcomes, reflecting the specific conditions under which the studies were conducted.

What Remains Uncertain About Metagon Research

A critical limitation documented in the evidence base is the insufficiency of data to establish the safety or effectiveness for children younger than 2 years of age. Regulatory reviews have determined that the certainty remains low for this population. Furthermore, because Metagon was studied in combination with other medications, isolating what effects are directly attributable to Metagon on patient-reported outcomes describing perceived discomfort is complex. Long-term effects are not fully established, and there is limited information for outcomes linked to chronic daily functioning.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Metagon (FAQ)

Q: Is Metagon the same type of medicine as [similar drug name]?

According to official classification, Metagon's active ingredient, Promethazine Hydrochloride, is a first-generation antihistamine and a phenothiazine derivative. This classification means it is chemically distinct from newer, more selective agents. Its mechanism of action involves non-selective blocking of multiple receptor systems, which contributes to its unique effects.

Q: Can Metagon be taken by people with kidney issues?

Official regulatory documents state that caution is required when Metagon is used in patients with renal (kidney) impairment. The prescribing information notes that use of the medicine requires careful evaluation in patients with kidney issues.

Q: Does Metagon cause drowsiness or affect driving?

Yes, official product information warns that Promethazine is highly likely to cause drowsiness or sedation. Because of this effect, the medicine may impair the mental and physical abilities needed to safely perform hazardous tasks, such as driving a vehicle or operating machinery. The potential for impairment is a primary safety consideration.

Q: Is it true that Metagon is a new drug?

Promethazine Hydrochloride is classified as a first-generation antihistamine. Regulatory evidence and historical context indicate that this is a well-established compound that has been used for several decades, distinguishing it from recently approved medications.

Q: Does Metagon interact with common pain relievers?

Regulatory-linked information suggests Metagon can be used with non-opioid pain relievers like paracetamol or ibuprofen. However, co-administration with opioid painkillers or other CNS depressants may increase or prolong the sedative effects.

Q: Is it okay to drink coffee while on Metagon?

Official regulatory labeling does not contain explicit warnings or restrictions against caffeine or coffee consumption. The primary warnings regarding substances concern alcohol and other medicines classified as CNS depressants, which can intensify the drug's effects.

Q: Are there different strengths or dosages of Metagon available?

Yes, the active ingredient is available in several official dosage forms and strengths. These include oral tablets of 12.5 mg, 25 mg, and 50 mg. Various strengths are also available for syrups and rectal suppositories.

Q: Are there specific times of day Metagon is recommended to be taken?

The recommended timing depends on the medical use context described in the product labeling. For certain allergy symptoms, an oral dose is often recommended before retiring (at bedtime). For motion sickness, it is taken 30 to 60 minutes before the start of travel.

Q: What is the purpose of the black box warning on Metagon's label, if any?

The official labeling contains a Boxed Warning (sometimes called a Black Box Warning). Its purpose is to draw attention to a serious safety concern: the risk of potentially fatal respiratory depression. This warning applies strictly to pediatric patients younger than two years of age.

Q: What are the most common reasons patients stop taking Metagon?

Official regulatory documentation states that sedation or drowsiness is the most prominent adverse reaction experienced by patients. This effect is often cited as a key factor influencing a patient's decision to discontinue or seek an alternative treatment.

Q: How does Metagon compare to placebo in clinical trials?

Studies reviewed by regulatory bodies confirm that Metagon is effective for its approved uses, such as managing allergy symptoms and controlling nausea. Research evidence indicates that patients receiving the medicine showed improvement in symptoms compared to the control group (placebo).

Q: How long does it usually take to feel the effects of Metagon?

The onset of action depends on the form of the medicine administered. According to official product information, effects are generally apparent within 20 minutes after oral administration. If the injection solution is used, effects can be apparent within five minutes.

Q: What is the difference between Metagon and generic versions?

Regulatory standards ensure that the active ingredient (Promethazine Hydrochloride) is identical in both the brand-name medicine and its generic versions. Generic products are approved only after meeting strict bioequivalence standards, meaning they are expected to perform the same as the original product.

Q: Does taking Metagon affect fertility?

Animal studies have been conducted to examine this issue. Regulatory documents note that Promethazine impaired fertility in male rats, but this occurred only at doses significantly higher than the maximum recommended human dose. The risk of this effect in humans has not been confirmed.

Q: How long does Metagon stay in your system?

Regulatory-linked pharmacokinetic data describes the elimination half-life of Promethazine in the body. This half-life is the time it takes for half the medicine to be cleared and is reported to range from 10 to 19 hours.

Q: Do people who stop taking Metagon experience withdrawal symptoms?

Official regulatory literature notes that Promethazine has the potential for abuse. Although physical dependence is not officially documented, withdrawal features have been reported in scientific literature following chronic, high-dose use.

Q: Where can I find the official patient information leaflet for Metagon?

The official patient information, often called the Medication Guide or Patient Information Leaflet (PIL), is available on government health websites. These documents can be found through national regulatory databases such as the NIH DailyMed service.

Q: Does Metagon interact with herbal supplements like St. John's Wort?

Official warnings advise caution with herbal remedies and supplements. Specifically, supplements that can cause drowsiness or anticholinergic side effects (like dry mouth) require caution, as Promethazine may worsen these effects.

Q: Can Metagon affect blood sugar levels?

Yes, regulatory information notes that an increase in blood glucose (blood sugar) has been reported in patients taking Promethazine. This is a potential effect documented in the official prescribing information.

Q: What is the risk of dependence or addiction with Metagon?

The regulatory label does not report a known potential for physical dependence with Promethazine. However, the potential for abuse is noted, and psychological dependence has been reported in scientific literature in some cases.

Q: What should be done if an adverse reaction is experienced?

Regulatory agencies strongly encourage the reporting of side effects to national health authorities, such as the FDA's MedWatch program, or to a healthcare provider. This helps track safety issues.

Q: How is Metagon eliminated from the body?

According to pharmacokinetic data, Promethazine is primarily metabolized (processed) in the liver into inactive compounds. These processed drug components are then eliminated from the body primarily through the urine and bile.

How should Metagon be stored and disposed of?

How to Store and Dispose of Metagon

Official regulatory documents define strict requirements for the storage and final disposal of Metagon to maintain drug quality and ensure public safety.

Storage Requirements

Condition	Requirement (Official Statement)
Temperature	Store strictly below 25 C (Controlled Room Temperature).
Handling	Do not freeze and protect from excessive moisture and light.
Packaging	Keep the product in the original container or carton until the time of use.
Child Safety	Keep out of the sight and reach of children in a secure location.

Disposal and Stability

Condition	Requirement (Official Statement)
In-Use Stability	If reconstituted, discard any unused portion after the labeled Beyond-Use Date (e.g., 28 days).
Disposal Method	Unused or expired Metagon must not be flushed down a sink or toilet or placed in household trash. Return the medicine to an authorized drug take-back program or pharmacy collection point for proper disposal.

Metagon